Humana (NYSE:HUM) Price Target Cut to $273.00 by Analysts at Barclays

Humana (NYSE:HUM - Get Free Report) had its target price dropped by Barclays from $322.00 to $273.00 in a report issued on Monday,Benzinga reports. The firm presently has an "equal weight" rating on the insurance provider's stock. Barclays's target price indicates a potential upside of 16.95% from the company's current price.

Several other equities analysts have also recently weighed in on the company. Raymond James upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a research note on Thursday, May 1st. Morgan Stanley lowered their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 12th. Oppenheimer lifted their price objective on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a report on Thursday, May 1st. Truist Financial decreased their price objective on Humana from $325.00 to $305.00 and set a "hold" rating for the company in a report on Monday, May 12th. Finally, Mizuho boosted their target price on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Sixteen investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $284.48.

Humana Stock Up 0.9%

Shares of HUM traded up $2.03 during trading hours on Monday, reaching $233.42. The stock had a trading volume of 1,129,385 shares, compared to its average volume of 1,778,382. Humana has a 12 month low of $212.45 and a 12 month high of $406.46. The firm has a 50-day simple moving average of $256.32 and a 200 day simple moving average of $266.21. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $28.17 billion, a price-to-earnings ratio of 23.46, a P/E/G ratio of 2.05 and a beta of 0.49.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 11.70% and a net margin of 1.02%. The business had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. During the same period last year, the business earned $7.23 EPS. The business's revenue was up 8.4% on a year-over-year basis. Equities research analysts predict that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. FPC Investment Advisory Inc. bought a new position in shares of Humana in the fourth quarter worth about $27,000. Centricity Wealth Management LLC bought a new position in shares of Humana in the fourth quarter worth about $30,000. Cary Street Partners Investment Advisory LLC raised its stake in shares of Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after buying an additional 46 shares during the period. LFA Lugano Financial Advisors SA raised its stake in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares during the period. Finally, Riverview Trust Co bought a new position in shares of Humana in the first quarter worth about $34,000. Institutional investors own 92.38% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.